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AdvocacyThis article addresses the educational issues associated with rare diseases (RD) and in particular the Neuronal
Ceroid Lipofuscinoses (NCLs, or CLN diseases) in the curricula of Health Sciences and Professional's Training
Programs. Our aim is to develop guidelines for improving scientiﬁc knowledge and practice in higher education
and continuous learning programs.
Rare diseases (RD) are collectively common in the general populationwith 1 in 17people affected by a RD in their
lifetime. Inherited defects in genes involved in metabolism are the commonest group of RD with over 8000
known inborn errors of metabolism. The majority of these diseases are neurodegenerative including the NCLs.
Any professional training program on NCL must take into account the medical, social and economic burdens
related to RDs. To address these challenges and ﬁnd solutions to them it is necessary that individuals in the gov-
ernment and administrative authorities, academia, teaching hospitals and medical schools, the pharmaceutical
industry, investment community and patient advocacy groups all work together to achieve these goals.
The logistical issues of including RD lectures in university curricula and in continuing medical education should
reﬂect its complex nature. To evaluate the state of education in the RD ﬁeld, a summary should be periodically up
dated in order to assess the progress achieved in each country that signed up to the international conventions
addressing RD issues in society. It is anticipated that auditing current practice will lead to higher standards and
provide a framework for those educators involved in establishing RD teaching programs world-wide.
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The neuronal ceroid lipofuscinoses (NCLs, also called Batten disease
or CLN disease) are relatively uncommon neurodegenerative condi-
tions, typically with an autosomal recessive inheritance pattern and
childhood onset. Though each of theNCLs has a distinct genetic etiology,
there is some phenotypic convergence between these disorders, which
are characterized phenotypically with vision loss (except Kufs), motor
and mental decline, seizures and premature death.
Despite their name and individual rarity, collectively, RD is paradox-
ically relatively common in the general population with 1 in 17 people
affected by a RD in their lifetime. Inherited defects in genes involved
in metabolism are the commonest group of RD with over 8000 known
inborn errors of metabolism. Within the metabolic diseases, a group of
over 70 lysosomal diseases represent a very signiﬁcant health care
burden, as they affect 1:5000 live births worldwide. The majority of
these diseases are neurodegenerative [1,2]. Although these conditions
are individually rare, their cumulative public health burden is substan-
tial, with 6–8% of people having a RD at some point during life.
In the past one to two decades, there has been an increased focus on
translational research spanning the spectrum frombench to bedside, in-
cluding natural history phenotyping studies and more recently, early
phase clinical trials for several of the forms of NCL (CLN1, CLN2,
CLN3). In addition, diagnostic accuracy has improved as genetic
diagnosis becomes increasingly available and affordable. Despite these
improvements, there remains a gap in medical knowledge about the
NCLs among clinical practitioners, both because of their rarity but also
because of the lack of emphasis in medical training upon rare diseases
in general and upon the NCLsmore speciﬁcally. The limitations of trans-
lational research in the NCLs are common to other inherited neurode-
generative diseases, especially those with monogenic inheritance such
as the lysosomal diseases. The challenges of translational science in
these diseases must be addressed in toto in an integrated manner, not
only in terms of speciﬁc medical issues associated with the use of
sophisticated diagnostics such as genetic sequencing, but also as
complex challenges to institutions and society as a whole.
Multidimensional aspects were considered in order to identify the
most appropriate guidelines to improve education on RD by seeking
the views of different stakeholders. The perspectives from science and
technology, health, education, civil society and the pharmaceutical
industry (Table 1) were taken into account. Using NCLs as a forum for
addressing medical education in RD, the major focus was to propose
guidelines for enhancing scientiﬁc knowledge and clinical practice in
the RD in higher education and continuous learning programs. The
resulting recommendations arose from a workshop conducted on
October 27th, 2014 at the National University Cordoba, Argentina, aTable 1
Complexity of translational research on RD.
Stakeholder Actions/goals
Scientiﬁc and technology institutes/research
institutes
Generate knowledge and techniques on e
pharmacology, clinical analysis, microsco
Healthcare Systems Provide neurology, pediatric neurology, n
nutrition and other medical specialties.
Extended clinical care and delivery Provide intramural and extramural care i
management at home, hospice, etc.
Centers of excellence Develop training in public hospitals to ma
on the evolution of diseases, shortening t
Provide coordination and liaison between
continuity of care and hospital treatment
Patients and patients advocacy groups Advocate for the rights of patients and the
system of solidarity between people with
Industry Develop orphan drugs using scientiﬁc and
standards.
International and national (regional)
regulations and conventions
International and National Organizations
the RD ﬁeld.
Academia, health science and medical schools To train scientists and professionals withpost-Congress activity of the 14th International Conference onNeuronal
Ceroid Lipofuscinoses (Batten Disease). Participants at this workshop
included medical faculty members with clinical and research experi-
ence in RDs, addressing but not limited to theNCLs, and an international
panel of NCL researchers and clinicians [3].
2. Methods
The international panel of delegates from academic centers in
Argentina, Germany, Italy, the United Kingdom and United States par-
ticipated in the post-congress Workshop to discuss the current global
state of medical education and training in RD, gaps in education and
proposed solutions. Delegates were tasked with identifying broad,
cross-disciplinary recommendations appropriate for all levels of medi-
cal education, frommedical curricula through to continuingmedical ed-
ucation (CME) teaching.
We also conducted a literature search via PubMed (www.ncbi.nlm.
nih.gov/pubmed/) using the keywords “rare diseases” and “medical ed-
ucation” in the title as well as the abstract. The publication dates were
limited to ten years starting in 2004, to include the recent classiﬁcation
changes. Each result was analyzed automatically by the searchmachine
for its relevance to the subject of medical education in rare diseases.
References meeting these criteria were retrieved and reviewed to fur-
ther determine if it matched the topics highlighted in the Workshop.
The main stakeholders identiﬁed and their actions/goals are summa-
rized in Table 1.
In addition to a literature search, we examined the websites of a
variety of international organizations devoted to RD, in order to deter-
mine if these organizations described programs or initiatives relevant
to medical education (including Orphanet, NORD, EURODIS, GRDR and
IRDiRC).
3. How can the complexity of the RD ﬁeld highlight education gaps?
3.1. Scientiﬁc and technology Institutes/Research Institutes
Research in RDs is chronically underfunded relative to common
neurodegenerative diseases [4]. This is despite the fact that single
gene disorders such as the RDs are easier to dissect at the molecular
and cellular levels, and therefore paradoxically advances in treatment
are much greater in RDs than in common polygenic diseases. Indeed
discoveries of disease mechanisms in RDs may well inform our under-
standing and treatment of common human diseases. For example,
links between lysosomal diseases and common diseases have been
made. This includes links between the lysosomal disease Gaucher dis-
ease and the development of Parkinson's disease. Another lysosomalxperimental models, cell biology, biochemistry, enzymology, proteomics, genomics,
py, image analysis, epidemiology, bioethics, etc.
europathology, genetics, radiology, ophthalmology, orthopedics, gastroenterology,
n kinesiology, speech therapy, nursing, aqua therapy, equinotherapy, patient
nage patients affected by RDs and employ speciﬁc algorithms for different RDs based
he time to diagnosis and providing access to available therapies.
institutions involved in translational research. Coordinate children and adults for
s over time.
ir families in the framework of existing laws and promote new legislation. Generate a
common needs, lowering anxiety and feelings of isolation of affected groups.
technical knowledge from academia and provide information on safety and quality
, Health Systems, Parliaments, etc. that regulate and follow the compliance of law in
expertise in all ﬁelds above.
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the protein that is defective serves as its receptor) and NPC patients de-
velop Alzheimer's symptoms and pathology [5,6]. The NCL diseases are
prone to epilepsy and therefore studying these single-gene disorders
will inform us about epilepsy and its causes. A major challenge for the
RD ﬁeld is that publishing in high impact journals is difﬁcult due to
lack of awareness about the signiﬁcance of these diseases by journal ed-
itors and reviewers. Case reports describe these very infrequent and
normally complex cases. Although case reports may rarely provoke a
change in working practice, they nonetheless provide important infor-
mation. They sometimes can serve as the catalyst for future clinical tri-
als. If this information is not available, the physician will have to start
from a position of minimal baseline information/insight. Furthermore,
it is in this type of situation when health professionals will refer to sci-
entiﬁc literature to ﬁnd solutions to a problem [7,8].
Increased research funding would allow greater progress and foster
international cooperation. As no individual country has sufﬁcient pa-
tients within its borders to improve diagnosis and therapy alone, inter-
national initiatives are therefore essential. Because of the rarity, no
single institution, and in many cases no single country, has sufﬁcient
numbers of patients to conduct clinical trials and translational research.
Geographic spread of patients has been a major impediment to recruit-
ment into clinical trials [9]. Universities, Governments, andNational and
International Scientiﬁc Agencies should increase the funding support
for RDs, as all the activities outlined above need long term ring-fenced
ﬁnancial support to succeed. The mechanistic links between rare and
common diseases means this investment will beneﬁt rare and common
diseases alike.3.2. Healthcare Systems
Diagnostic delay is a major challenge particularly as we now have
disease-modifying therapies for some of these RDs. Very signiﬁcantly,
diagnostic delaymeans families maywell havemultiple children before
the affected child is diagnosed [10]. Getting an accurate diagnosis
remains a major challenge for many people with RD and is vital to
ensure that informed reproductive choices can be made.
The technologies of molecular, cellular, emerging analytical
technologies and bioinformatics also need teaching in the context of
RD research and treatment. Progress in developing therapies has result-
ed in the approval of nine enzyme replacement therapy products for
Lysosomal Disease by the FDA of the USA [11]. These clinical trials
have demonstrated how important good trial design and validated bio-
markers are to the success of clinical trial outcomes and when dealing
with small patient numbers a different regulatory paradigm is needed.
These aspects need to be taught at all levels of basic and translational
science in the RD ﬁeld. Translational science needs to be a priority in
both medical and research specialty teaching. Indeed, translational
research and education must go hand in hand.3.3. Clinical care and delivery
The national care system for neurodegenerative diseases must be
expanded to include children and young adults with RD. The care
costs must bemet by the state. Separate funding to pay for RD therapies
is needed in each country, as these therapies are expensive due to low
patient numbers. Also, where effective therapies have been developed,
they often involve lifelong treatment (e.g., enzyme replacement) rather
than a one-time intervention. This also increases the cost. Also, many
available treatments, though effective, are not curative. Therefore, pa-
tients still require ongoing care and services, albeit perhaps at a lower
level than if they had not received any treatment at all. RDs are interdis-
ciplinary and bringing specialists together into specialist centers will
speed progress and improve patient outcomes.3.4. Centers of excellence
Centers of excellence on RDs are essential to ensure expert clinicians
whohave seenmultiple cases, treat patients. This is adopted in somebut
not the majority of countries.
These centers should be comprised of experts in different areas of
knowledge. The experts within each Center also need to work together
in an interdisciplinary team (Neurologists, Radiologists, Ophthalmolo-
gists, Cardiologists, Biologists, Biochemist, Geneticists, Molecular
Biologists, Nutritionists, Dentists, Psychiatrists, Psychologists, etc.) for
the study of RDs. In this sense, Centers of Excellence provide a “medical
home” for individuals with RD and speeds the process of achieving a di-
agnosis. A great advantage of this model is the association among these
Centers of Excellence with Universities to conduct research to under-
stand disease mechanisms and innovate new therapies. Consolidating
patient cohorts also allows for: better physician/practitioner learning
clinical database design, enrollment and maintenance establishment
of biorepositories. This must be done at both the national and interna-
tional levels.3.5. Patients and parents advocacy groups
The lysosomal disease community is very active at the clinical,
scientiﬁc and patient organization levels. However, access to clinical
and social care is very variable between and even within countries pos-
ing a signiﬁcant challenge to the health system and patients and their
families [12]. The key limitations include lack of knowledge about RDs,
insufﬁcient medical research on causes and the course of RDs, as well
as challenges for patient organizations to work together and pool their
resources and know how.
The main role of patient's organizations is to advocate to improve
legislation through the generation and/or regulation of national and in-
ternational laws for RD using the highest standards. The individual
countries through these national laws should provide medicines, social
care, help improve and speed the process of diagnosis, follow patients’
long term and provide genetic counseling and other services.
Families need to organize themselves in NGOs to raise awareness
using a variety of media (radio, television, magazine articles etc.) to
raise awareness and advocate approaches to solve the problems
they face (e.g. diagnostic delay and access to treatments) in order
to make the challenges associated with RDs visible to the whole of
society. They can also highlight best practice in different countries
so that more regions improve their health care systems to better
treat patients with RDs. The creation of Web pages with comprehen-
sive and fully integrated information on RDs, with options that in-
clude different languages, access for families and health care
professionals and include information about Centers of Excellence
and Family Associations, provide a very useful tool (Table 3). This is
necessary and important because families have Internet access, but
can't easily evaluate the quality of the information provided on the
various disparate web sites that currently exist. Dedicated profes-
sionals or experts in RDs are needed to validate and ﬁlter the infor-
mation to maximize the beneﬁt of this information. Advice on
unproven/unregulated experimental therapies and their risks also
needs to be available to patient's families understandably desperate
for supposed “cures” for their children.
International alliances of patient groups will help foster new groups
in different countries and support their initiation. Legal frameworks to
promote the formation of patient organizations and providing represen-
tatives for these activities in national parliaments would be highly
desirable. According to the European Commission RD 2014 [1], recom-
mendations are to have ﬁnancial support through the tax system for
companies to promote the funding of patient organization and scientiﬁc
meetings. Equality of access between companies and the research
community needs to be ensured. Company registries need to be open.
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and ethical issues, although this is not yet common practice.
3.6. Industry
RD has traditionally received far less attention from pharmaceutical
companies than more common diseases. RD have often been
overlooked because of a myriad of reasons including: lack of research
on the disease state, difﬁculty inﬁnding and retaining patients to partic-
ipate in clinical trials, getting coverage approvals frompayers, spreading
market awareness about the disorder and the ﬁnancial return of such
therapies [13,14].
Investigating the strengths and limitations of the current develop-
ment pathways for new drugs, medical devices, and biologics for rare
diseases would give a basis for further and innovative developments.
Signiﬁcant collaborative partnership is required in areas of medical
research and product development. The relationships between the
pharmaceutical industry, foundations, patient-advocacy groups, aca-
demic and government investigators and funding programs, regulatory
bodies, and reimbursement agencies need to be analyzed in an educa-
tional context to evaluate their impact on people with RDs [15]. The sci-
entiﬁc and technical knowledge should be translated in order to
develop safe drugs with greater efﬁcacy and better quality standards
and that are accessible to all patients.
3.7. International and national (regional) regulations and conventions
1. The recent report of the Scientiﬁc Secretariat of the European Union
Committee of Experts on Rare Diseases (EUCERD) aims to provide an
informative and descriptive overviewof RD activities at the European
Union (EU) and Member State (MS) level in the ﬁeld of RD and or-
phanmedicinal products up to the endof 2013. Regarding education-
al issues, some countries have made remarkable progress. For
example, France was the ﬁrst EU country to adopt, at the end of
2004, a comprehensive RD plan with allocated funding, including
the key objective to train health professionals to better identify RD.
Greece has upgraded services for diagnosis, therapy and rehabilita-
tion of RD patients with emphasis on training of health care profes-
sionals to improve diagnosis and access to high quality health care.
Bulgaria has created and endorsed the professional qualiﬁcation of
medical specialists in the ﬁeld of early diagnostics and prevention
of RD.
The Spanish strategy for RDs includes education and training. The
evaluation has also shown that it is necessary to implement actions
aimed at collecting and disseminating information and resources
available on RDs, to increase training of primary health care profes-
sionals, on diagnosis of RDs and to establish adequate criteria for re-
ferral, to improve the availability of basic health information to the
teaching staff that cares children with RDs.
The Czech Republic National Strategy includes the goal of improving
information and education. The Netherlands has made a statement
about the key bottlenecks for the plan, including lack of knowledge
about RDs, insufﬁcient medical research on causes and the course
of RDs as well as the inability of some patient organizations to
work well together. The plan recommends emphasizing knowledge
about RDs through training and the establishment of expert centers,
making information widely accessible to diverse audiences; making
ﬁnancial resources available for research and development of treat-
ments as well as maintaining consistent policy for claims and
reimbursement of orphan drugs. In 2013 the United Kingdom
Government published a strategy on rare diseases, that contains
over 50 commitments in 5 main areas, with the aim of ensuring
that people living with a rare disease have access to the best possible
evidence-based care and treatment from health and social services,
via working together with charities, researchers and industry [16].
In Germany a total of 52 policy proposals have been included in therespective plan covering 7 action ﬁelds one of them related to Infor-
mation Management, Medical and Dental Training and Continued
Education.
2. The National Organization for Rare Disorders (NORD) [17] in the
USA, is a unique federation of voluntary health organizations dedi-
cated to helping people with rare “orphan” diseases and assisting
the organizations that serve them. NORD is committed to the identi-
ﬁcation, treatment, and cure of rare disorders through programs of
education, advocacy, research, and service.
When NORD conducted an informal survey on this topic among so-
cial media followers, they found that it took ﬁve years or longer to
get an accurate diagnosis for 40% of those who responded (NORD).
This situation highlights that getting an accurate diagnosis still re-
mains a major challenge for many people with RDs. The US Food
and Drug Administration, a governmental agency, also has the
“Ofﬁce of Orphan Products Development” which is a speciﬁc ofﬁce
within the FDA to advance treatments for rare diseases [18]. Within
theNational Institutes of Health (NIH), there is the Ofﬁce of Rare Dis-
ease Research (ORDR) to identify, stimulate, coordinate, and support
research to respond to the needs of patients who have any one of the
approximately 6800 rare diseases known today [19].
3. The Charter on Human Rights and Bioethics, of the United Nations,
2005 [20]: in dealing with ethical issues raised by medicine, life sci-
ences, and associated technologies as applied to human beings. The
Declaration, as reﬂected in its title, anchors the principles it endorses
in the rules that govern respect for human dignity, human rights and
fundamental freedoms. By ensuring bioethics in international human
rights and by ensuring respect for the life of human beings, the Dec-
laration recognizes the interrelation between ethics and human
rights in the speciﬁc ﬁeld of bioethics.
The relationship of Bioethics education, training and information is
considered by Article 23: In order to promote the principles set out
in this Declaration and to achieve a better understanding of the
ethical implications of scientiﬁc and technological developments, in
particular for young people. States should endeavor to foster bioeth-
ics education and training at all levels as well as to encourage infor-
mation and knowledge dissemination programs about bioethics.
4. The purpose of the Convention on the right of persons with disabil-
ities [21] is “to promote, protect and ensure the full and equal enjoy-
ment of all human rights and fundamental freedoms by all persons
with disabilities, and to promote respect for their inherent dignity.
Persons with disabilities include those who have long-term physical,
mental, intellectual or sensory impairments which in interaction
with various barriersmay hinder their full and effective participation
in society on an equal basis with others”. This convention used a dif-
ferent approach than the RD speciﬁcally.
5. The health-related quality of life (HRQOL) in childrenwith inborn er-
rors of metabolism IEM and co-existentmovement disorder is signif-
icantly reduced compared to other chronic, stigmatizing disorders.
Delay in adaptive functioning and amore severe movement disorder
were associated with a lower HRQOL. Accurate classiﬁcation of
movement disorders, particularly in the context of complicated,
multi-organ disorders, is likely to aid therapeuticmanagement, espe-
cially since effective therapeutic options are available. It is necessary
for greater awareness of the presence of movement disorders since
targeted therapiesmight lead to improvedmotor function and possi-
bly subsequent overall quality of life [22]. Research data on psycho-
social factors in rare inborn errors of metabolism patients are
generally sparse. However, the growing interest in the topic is
underlined by the fact that seven of the 11 articles reviewed were
published in 2012 or 2013. Multicenter studies and the use of a stan-
dardized, disease-speciﬁc assessment tools are needed to establish
health-related quality of life-as an important additional outcome pa-
rameter in patient-centered research and clinical trials on RD [23].
6. A call for action to improve access to care and treatment for patients
with rare diseases in the Asia-Paciﬁc region to improve access to care
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(a) developing legislative deﬁnitions to confer enforceable protec-
tion, (b) creating or strengthening policies by objectively measuring
the impact brought about by rare diseases and establishing platforms
to reach out to the rare disease community, and (c) fostering collab-
oration across sectors and countries. It is hoped that these suggested
actions can catalyze discussions and progress in the region [24].
The Human Varioma Project (HVP) [25] was started in 2006. The
goals aremanybut primarily to generate a complete record including
genetic data and all other information that may modify the clinical
phenotype. It is an international megaproject. Collection is done at
a national and at a regional level. It has now expanded to an active
and growing Consortium of 81 countries that collaborate to develop
and maintain the necessary standards, systems and infrastructure to
support global-scale genomic knowledge sharing.
7. In Latin America, the Center for Research on Inborn Errors of Metab-
olism in Córdoba-Argentina (CEMECO) has gathered experience for
more than 30 years in translational research and providing services
to RD affected patients. The ﬁeld of RD is very active in Latin
America and the Latin American Society of Inborn Errors of Metabo-
lism andNeonatal Screening (SLEIMPN) organizes conferences in the
region every two years. It recently developed an online Journal based
in Brazil devoted to RDs and associated issues, entitled the Journal of
Inborn Errors of Metabolism and Screening (JIEMS) [26]. A National
Law for RD was approved by the National Parliament of Argentina
in 2011 [27].
3.8. Academia, Health Science and Medical Schools
In contrast with the remarkable progress made by government
agencies on the RDs, the academic sector lacks initiatives to improve
the knowledge of health professionals on complex topics such as RDs.
To train scientists and other professionals in RD changes are needed in
Academia, Health Science Training and Medical Schools.
RD education is lacking worldwide, particularly in medical training
with no specialized courses on the clinical picture, models of disease,
therapeutic interventions and the social and ethical issues around RDs.
Another deﬁcit in theHealth Sciences curricula is related to the teaching
of clinical features of patients affected with RD. Medical doctors cannot
suspect or study conditions that they do not know exist. Therefore, it is
important to ensure the inclusion of RDs early in medical careers and
promote postgraduate courses for differentmedical and connected spe-
cialties involved in the care of children.
Education on clinical research and experimental medicine, and its
role in understanding diseases and developing novel therapies is not
taught in most universities. The translational process needs to be ex-
plained and stimulated through teaching and links with basic and phar-
maceutical industry scientists [28]. Teaching needs to focus on how to
maximize patient, scientiﬁc and company interactions.
The teaching of ethical issues is essential for research with both
humans and in animal models [29]. Patients with low income often
fail to access specialized services and treatments leading to social and
medical inequality. Therefore, it is important to develop recruitment
and subject engagement practices that will increase diversity with re-
spect to access and participation in clinical trials. The ethical and practi-
cal challenges associated with tissue banks, organ donation post-
mortem and the sources of control human material also need greater
discussion and teaching [30].
Mechanisms to prevent potential corruption and manage conﬂict of
interest and best practice guidelines should also bedeveloped in parallel
and should not be viewed as an obstacle to cross-sector collaborations.
Regulatory agencies need to be educated on the fact that trial design
and implementation differs in the RD ﬁeld in order to preserve the prin-
ciples proclaimed in the Charter on Human Rights and Bioethics, of the
United Nations 2005 [20]. Some countries have similar declarations or
national acts.Screening and prevention strategies, including pre-natal diagnosis
and pre-implantation embryo selection techniques need considering
in the RD context [31]. International patient registries need creating/
unifying and must be governed in perpetuity by the patient
communities/researchers not by the pharmaceutical industry. Interna-
tional equity needs to be achieved for reproductive choices, including
screening, termination of pregnancy and access to embryo selection
technologies. Quality of life is sanctity of life [22,23].
Any professional training program on NCL or other RDs must take
into account the medical, social and economic burdens associated
with RDs:
1. To understand the widespread impact of NCL as RDs: with an
estimated 8000 or more different metabolic RD in the world, there
are many individuals who require specialized services and under-
standing of their rare condition.
2. To appreciate the need for interdisciplinary care of children: it is im-
portant for children to have a team of health care providers who
communicate with one another and work together for the beneﬁt
of the child.
3. Importance of supporting the psychosocial needs of the family: in
educational settings, medical students, residents, fellows should all
receive training in how to be sensitive to the needs and burdens
upon the family, in relation to the child's illness. They should be
trained in how to give the diagnosis with sensitivity and compassion
and provide information on organizations devoted to supporting in-
dividuals and their families affected by RD.
4. Importance of training in ethical matters related to both clinical care
and clinical research.
5. Importance of training (at the post-graduate level — for residents/
fellows) in the ﬁelds of clinical research and experimental therapeu-
tics. In the course of their clinical training, physicians can learn how
to administer a particular treatment, but better still, we urge a
model in which physicians will have opportunities to be trained in
how to investigate and develop new treatments — to not simply be-
come physicians who “use” the existing science to treat children, but
rather, professionals who contribute to the development of new
knowledge.
The suggested guidelines speciﬁc to NCL are intended to highlight
the importance of the following items:
1. To recognize the differences among the different genotypes and
phenotypes of the NCLs. Not all NCLs are created equal. For example,
children with CLN1 and CLN2 diseases often develop intractable
seizures, whereas seizures are less common and more easily man-
aged in CLN3 disease [32]. Thus, seizure management will be differ-
ent and may be speciﬁc to the genetic type. Indeed, some
commonly used drugs are detrimental for NCL patients, clinicians
need to know this [33].
2. To develop conﬁdence in providing care for childrenwith theNCLs. It
would be very helpful to have consultation with an expert, and from
that consultation, local physicians should begin to feel conﬁdent in
following the treatment plan suggested by the expert disseminating
this knowledge and best practice. Also, though some symptoms are
uniquely managed because of the NCL diagnosis, many can be man-
aged with the existing good standard of care.
3. To shorten the time to diagnosis. There should be training in how to
access diagnostic services including newborn screening and the
ﬁnancial resources available to pay for the diagnostic testing so that
economically disadvantages families are not prevented from
receiving diagnosis in a timely fashion.
4. To provide care (or arranging care) for associated features. For exam-
ple, a dentist who has cared for many children with other RDs is
aware that these children require specialized attention and that
often their dental health is neglected (P. K de Hidalgo, personal com-
munication). Though poor dentition is not an NCL-speciﬁc symptom,
2321I.A. Cismondi et al. / Biochimica et Biophysica Acta 1852 (2015) 2316–2323it can develop simply because these children are difﬁcult to care for
in general. Dental health is one example, but there are many other
general health issues that need to be considered as well.
5. The changes in themedical and health science undergraduate curric-
ula could begin with the identiﬁcation of spaces in current courses
where an introductory lecture on RDs can be inserted. This would
cover: general concept of genetic disorders; lysosomal diseases in
general; clinical presentation; existing therapies and experimental
approaches. At the Postgraduate level: workshops can be run with
the aim to go into more detail of a particular disease (NCL), genetic
causes, cell biology, model systems, experimental therapies and fu-
ture prospects for trials. The logistical issues include the need to
know current course structures and where best to place these lec-
tures (in a RD theme), the selection of an adequate lecturer or team
to deliver these lectures, the reinforcement of ideas through tutorials
(on line or face to face) and the assessment of the students via exams.
In recent years, some innovative learning approaches have been pro-
posed to increase health professionals training and awareness on RD
[34,35].4. Discussion
The delegates agreed on the need for an innovative integration of
RDs into the medicine curriculum as well as in Continuing Professional
Development (CPD) and Continuing Medical Education (CME). The
complexity of RDs requires a broad understanding of a variety of con-
cepts including the implications of diagnostic delay, quality of life, re-
spect for patient's family opinions, equity of access to treatments, all
within a strong ethical framework. The literature retrieved from biblio-
graphic databases, such as PubMed, was very limited on the topic of ed-
ucational issues in RDs. Evenwhen the numbers of citations on RDswas
expanded to include the last 10 years (from 5754 in 2005 to 12,646 in
2014), the articles regarding medical education numbered 377 for the
entire period. When these articles were manually analyzed their rele-
vance was very low. Only one article from the 377 includes in the title
both term “Rare diseases” and “medical education” [36]. In theOrphanet
Journal of Rare Disease (OJRD) a search in the same period retrieved 64
citations and only 2 included both terms in the title [34,37]. Both cita-
tions are abstracts of oral presentations from the 5th European Confer-
ence on Rare Diseases (ECRD 2010). More relevant information can be
accessed on web sites such as Orphanet, NORD, EURODIS and others.Table 2
Model for strategies and guidelines for education improvements on RD. Modiﬁed from http://
general conclusions and guidelines.
Current situation Recommendations
Lack of awareness and identiﬁcation of
RD among healthcare professionals,
resulting in a delay in diagnosis or
misdiagnosis of RD patients.
1. Increase healthcare professionals'
knowledge and awareness of RD:
a. RDs
b. CPD
c. Med
d. e-le
2. Need for improved linkage
between specialist centers and
local healthcare professionals.
a. Sta
b. For
educa
c. ‘Hu
and lo
Difﬁcult for both professionals and
patients to access reliable, up-to-
date information on RDs and
who the specialist(s) is/are in a
particular condition.
3. Improve access to reliable information
on RDs to make it easier for the public
and professionals to obtain information.
a. Onl
and g
b. App
inform
c. Ens
d. Res
Testin
e. Tra
projec
f. GuiThese data support the conclusion that the issue of medical education
in RDs is not “speciﬁcally” described in the articles analyzed, although
in some paragraphs tangentially mentioned the necessity of including
RDs in the curricula.
Table 2 reports on the current situation of education on RD in a con-
densed format. The Table summarizes the recommendations and tar-
gets for challenges to be accomplished by different countries with
regard to the international regulations and conventions. To follow the
progress and evaluate the state of the education in the RD ﬁeld, such a
summary should be periodically updated in order to assess the progress
achieved in each country that signed the international conventions in-
volving RD issues. Table 3 provides a list of NCL resources. There are
other sites that have a more focused emphasis on registries (DEM-
Child; Massachusetts General Hospital's Registry & tissue bank).5. Challenges
Health care professionals need formal training in RDs as a corner-
stone of medical training. Getting an accurate diagnosis in a rapid
timeframe is essential but still remains challenging even in developed
countries. Other challenges include developing the basic tools re-
searchers need, such as longitudinal natural history studies and encour-
aging a more collaborative approach to medical research, as is
advocated in a new law enacted in recent years (26,689 2011-
Argentina the National Pediatric Research Network Act of 2013-USA).
Funding of basic and applied research in RDs is essential. This should
be signiﬁcantly expanded and ring-fenced for RDs.
The new initiative on Precision Medicine [38] will encourage and
support the next generation of scientists to develop creative new ap-
proaches for detecting, measuring, and analyzing a wide range of bio-
medical information. The RD community can contribute very
signiﬁcantly to this endeavor.
Assuring patient access to therapies remains a challenge and must
be one of the priorities to resolve. Far too often, we see individuals
and families struggling to gain access to the medical care and services
they need. To address the challenges and ﬁnd solutions is necessary
that individuals in the government and administrative authorities, aca-
demia, teaching hospitals and medical schools, the pharmaceutical in-
dustry, investment community and patient advocacy groups all work
together to achieve these goals. The fundamental conclusion from the
workshop is that wemust start with better education on RDs aswithoutwww.raredisease.org.uk/documents/RD-UK-Strategy-Report.pdf and integrated with the
Target of recommendation
module in medical curriculum.
/CME training.
ical care providers training in basic genetics.
arning packages by qualiﬁed professionals.
Medical and health science schools.
Health departments
The Academia under the guidance of
National Health Systems
ff exchanges for information update.
mal recognition of specialist centers teams'
tional role.
b and spoke’ model between specialized
cal services
Clinical service managers, healthcare
professionals.
National Health System, patient
organizations.
Commissioners. Rare Disease ONGs
TV media set
ine portal linking to reliable information
uidelines.
raisal of healthcare professionals'
ation needs and gaps in existing resources.
ure Orphanet funding.
ponsible clinician in a Directory of Genetic
g.
ining on the use of diagnostic tools as part of
ts.
delines “index of suspicion” to doctors.
All health departments.
Joint Committee on Medical Genetics,
Colleges and Deans of Health science
and medical schools Department of
Health.
Funding bodies.
Joint Committee on Medical Genetics.
Table 3
NCL and general rare disease patient support and advocacy groups.
Organization Country Website
NCLs
Asociación Española de Familias Afectadas por
Lipofuscinosis (Aefal)
Spain www.aefal.org
Associazione Italiana per la NCL Italy www.ceroidolipofuscinosi.it
Australian Batten Disease and Support Association Australia www.battens.org.au
Bartimeus Netherlands www.bartimeus.nl
Batten Disease Family Association (BDFA) United Kingdom www.bdfa-uk.org.uk
Batten Disease International Alliance (BDIA) United Kingdom www.bdfa-uk.org.uk/batten-disease-international-alliance
Batten Disease Support & Research
Association (BDSRA)
USA www.bdsra.org
Bee for Battens Ireland www.beeforbattens.org
Beyond Batten Disease Foundation (BBDF) USA www.beyondbatten.org
Contact Punkt NCL Belgium www.contactpuntncl.be
Dansk Spielmeyer–Vogt Forening/Danish NCL
Family Association
Denmark www.dsvf.dk
Finnish INCL Association (Suomen INCL yhdistys) Finland www.incl.ﬁ
“Life” Association against child rare illness Serbia www.zivotorg.org
Lysosomal Diseases New Zealand (LDNZ) New Zealand www.ldnz.org.nz
NCL-Gruppe Deutschland e. V. Germany www.ncldeutschland.de
NCL Resource — a gateway for batten disease United Kingdom www.ucl.ac.uk/ncl/familysupport.shtml
Norsk Spielmeyer-Vogt Forening (NSVF) Norway www.nsvf.org
SSVF — Svenska Spielmeyer-Vogt Föreningen Sweden www.ssvf.nu
The Children's Brain Diseases Foundation (CBDF) USA nd
Rare Diseases in General
Alianza Iberoamericana de Enfermedades
Raras (ALIBER)
Argentina, Brazil, Colombia, Ecuador,
Guatemala, Mexico, Portugal, Spain,
Uruguay and Venezuela
www.aliber.org
Asociación de Pacientes de Enfermedades Lisosomales Argentina www.apelra.org.ar
Canadian Organization for Rare Disorders (CORD) Canada www.raredisorders.ca
Children Living with Inherited Metabolic
Diseases (Climb)
United Kingdom www.climb.org.uk
Contact a Family United Kingdom www.cafamily.org.uk
Fundación Geiser Argentina www.fundaciongeiser.org
Gene Reviews USA www.genereviews.org
International Conferences for Rare Diseases and
Orphan Drugs
Sweden www.icord.se
National Center for Biotechnology Information-
Genetic Testing Registry
USA www.ncbi.nlm.nih.gov/gtr
National Organization for Rare Disorders (NORD) USA www.rarediseases.org
ORDR Ofﬁce for Rare Disease Research USA www.rarediseases.info.nih.gov
Rare Diseases Europe (EURODIS) Europe (International) www.eurodis.org
Clinical Care & Research Centers for the NCLs
Blue Bird Circle Clinic Texas USA www.texaschildrens.org
Centro de Manejo Integral de Enfermedades Raras
(CEMINER)
Chile www.redclinica.cl
Children's National Hospital Columbus, OH USA www.nationwidechildrens.org
eUniversity of Rochester Batten Center, NY USA www.urmc.rochester.edu/neurology/batten-disease-center
Evelina London Children's Healthcare: Batten
disease service London
United Kingdom www.evelinalondon.nhs.uk/our-services/hospital/batten-clinic/
overview.aspx
Gifu University Japan www.hosp.gifu-u.ac.jp/eng/index.html
Hospital de Clinicas-Porto Alegre Brasil www.hcpa.ufrgs.br/
Hospital das Clinicas-Universidade de Sao Paulo Brazil www.hc.fm.usp.br
Hospital de Niños de Córdoba Argentina www.Hospitaldeninos.com/ar/hn/index.php
Instituto de Errores Innatos del Metabolismo
Pontiﬁcia Universidad Javeriana
Colombia www.javeriana.edu.co/ieim
Instituto de Nutrición y Tecnología de los Alimentos Chile www.inta.cl
Instituto Nacional de Medicina Genómica Mexico www.inmegen.gob.mx
Instituto Nacional de Pediatría Mexico www.pediatria.gob.mx
Massachusetts General Hospital Boston USA www.massgeneral.org
Orphanet Armenia, Austria, Belgium, Bulgaria,
Canada, Croatia, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France,
Germany, Ireland, Israel, Italy, Latvia,
Lebanon, Lithuania, Morocco, Netherlands,
Norway, Poland, Portugal, Romania, Servia,
Slovakia, Slovenia, Spain, Sweden,
Switzerland, Turkey, United Kingdom
www.orpha.net
SeeAbility United Kingdom www.seeability.org/our-specialisms/book/juvenile-batten-disease
Servicio de Neurología Hospital Clínico San Borja-Arriarán Chile www.hospitalclinicosanborjaarriaran.gob.cl
Women's and Children's Hospital, N. Adelaide Australia www.wch.sa.gov.au
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reality.
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